Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 90-95

  Hahn, Margaret ^a,b   Chintoh, Araba ^a,b   Giacca, Adria ^a   Xu, Li ^a   Lam, Loretta ^a   Mann, Steve ^a,b   Fletcher, Paul ^b,c   Guenette, Melanie ^a,b   Cohn, Tony ^b,c   Wolever, Tom ^c   Arenovich, Tamara ^b   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical antipsychotics; Diabetes; Dopaminergic; Histaminergic; Insulin secretion; Metabolic; Muscarinic; Receptor binding; Serotonergic

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUPRENORPHINE; C PEPTIDE; DARIFENACIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUCOSE; HISTAMINE RECEPTOR; INSULIN; KETANSERIN; MUSCARINIC RECEPTOR; RACLOPRIDE; SEROTONIN RECEPTOR; TERFENADINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RECEPTOR BINDING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; C-PEPTIDE; DISEASE MODELS, ANIMAL; GLUCOSE; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MALE; PROTEIN BINDING; RADIOIMMUNOASSAY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M3; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE;

EID: 80051782701     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.06.004     Document Type: Article

References (46)

1. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., Bergman R.N. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005, 54(3):862-871.
2. Bell J.K., McQueen D.S., Rees J.L. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br. J. Pharmacol. 2004, 142(2):374-380.
3. Bergman R.N., Finegood D.T., Kahn S.E. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur. J. Clin. Invest. 2002, 32(Suppl 3):35-45.
4. Chaouloff F., Laude D., Baudrie V. Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur. J. Pharmacol. 1990, 187(3):435-443.
5. Cheng J.T., Chi T.C., Liu I.M. Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton. Neurosci. 2000, 83(3):127-133.
6. Chintoh A.F., Mann S.W., Lam L., Lam C., Cohn T.A., Fletcher P.J., Giacca A., Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J. Clin. Psychopharmacol. 2008, 28(5):494-499.
7. Chintoh A.F., Mann S.W., Lam L., Giacca A., Fletcher P., Nobrega J., Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr. Res. 2009, 108(1-3):127-133.
8. Chiu C.C., Chen K.P., Liu H.C., Lu M.L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J. Clin. Psychopharmacol. 2006, 26(5):504-507.
9. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979, 237(3):E214-E223.
10. Devedjian J.C., Pujol A., Cayla C., George M., Casellas A., Paris H., Bosch F. Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. Diabetologia 2000, 43(7):899-906.
11. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996, 19(3):278-286.
12. Garcia-Tornadu I., Ornstein A.M., Chamson-Reig A., Wheeler M.B., Hill D.J., Arany E. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010, 151(4):1441-1450.
13. Gautam D., Han S.J., Duttaroy A., Mears D., Hamdan F.F., Li J.H., Cui Y., Jeon J., Wess J. Role of the M3 muscarinic acetylcholine receptor in beta-cell function and glucose homeostasis. Diabetes Obes. Metab. 2007, 9(Suppl 2):158-169.
14. Gautam D., Jeon J., Starost M.F., Han S.J., Hamdan F.F., Cui Y., Parlow A.F., Gavrilova O., Szalayova I., Mezey E., Wess J. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci U S A 2009, 106(15):6398-6403.
15. Geyer M.A., Krebs K.M. Serotonin receptor involvement in an animal model of the acute effects of hallucinogens. NIDA Res. Monogr. 1994, 146:124-156.
16. Gilles M., Wilke A., Kopf D., Nonell A., Lehnert H., Deuschle M. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom. Med. 2005, 67(5):748-751.
17. Gilon P., Henquin J.C. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr. Rev. 2001, 22(5):565-604.
18. Hajduch E., Rencurel F., Balendran A., Batty I.H., Downes C.P., Hundal H.S. Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J. Biol. Chem. 1999, 274(19):13563-13568.
19. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32(2):289-297.
20. Jin H., Meyer J.M., Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 2002, 14(1):59-64.
21. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., Gibbs E.M., Zawalich W.S., Rollema H. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54(5):1552-1558.
22. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
23. Leslie D.L., Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychiatry 2004, 161(9):1709-1711.
24. MacDonald M.J. Glucose-stimulated expressed sequence tags from rat pancreatic islets. Mol. Cell. Endocrinol. 1996, 123(2):199-204.
25. Mahar Doan K.M., Wring S.A., Shampine L.J., Jordan K.H., Bishop J.P., Kratz J., Yang E., Serabjit-Singh C.J., Adkison K.K., Polli J.W. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 2004, 72(2):92-98.
26. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001, 50(2):385-391.
27. Matsui-Sakata A., Ohtani H., Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 2005, 20(5):368-378.
28. McCall R.B., Harris L.T. 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur. J. Pharmacol. 1988, 151(1):113-116.
29. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25(3):390-392.
30. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19(Suppl 1):1-93.
31. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59(4):337-345.
32. Paulmann N., Grohmann M., Voigt J.P., Bert B., Vowinckel J., Bader M., Skelin M., Jevsek M., Fink H., Walther D.J. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS. Biol. 2009, 7(10):e1000229.
33. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V., Pipek R., Iozzo P., Lancaster J.L., Cincotta A.H., DeFronzo R.A. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23(8):1154-1161.
34. Pi-Sunyer F.X. Medical hazards of obesity. Ann. Intern. Med. 1993, 119(7):655-660.
35. Rattigan S., Clark M.G., Barrett E.J. Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Diabetes 1999, 48(3):564-569.
36. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 1999, 60(Suppl 10):5-14.
37. Roth B.L., Sheffler D.J., Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 2004, 3(4):353-359.
38. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 2005, 280(44):36824-36832.
39. Sakata T., Fukagawa K., Fujimoto K., Yoshimatsu H., Shiraishi T., Wada H. Feeding induced by blockade of histamine H1-receptor in rat brain. Experientia 1988, 44(3):216-218.
40. Satin L.S., Kinard T.A. Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit?. Endocrine 1998, 8(3):213-223.
41. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994, 15(7):264-270.
42. Silvestre J.S., Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find. Exp. Clin. Pharmacol. 2005, 27(5):289-304.
43. Starrenburg F.C., Bogers J.P. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur. Psychiatry 2009, 24(3):164-170.
44. Teff K.L., Townsend R.R. Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-Peptide secretion in humans. J. Clin. Endocrinol. Metab. 2004, 89(11):5606-5613.
45. Wadenberg M.L., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 2000, 150(4):422-429.
46. Wang K.Y., Tanimoto A., Yamada S., Guo X., Ding Y., Watanabe T., Hirano K., Tsukada H., Sasaguri Y. Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am. J. Pathol. 2010, 177(2):713-723.